This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Movahed, M.-R. Articles by Bryan, C. S. Search for Related Content PubMed Articles by Movahed, M.-R. Articles by Bryan, C. S. Social Bookmarking                         What's this?

Prophylactic Use of Vancomycin in Adult Cardiology and Cardiac Surgery

Department of Medicine, Division of Cardiology, University of California, Irvine Medical Center, Orange, California; University of California, Irvine Medical Center, Division of Cardiology, Building 53, Route 81, Rm 100, 101 The City Drive South, Orange, CA 92868- 4080; mmovahed{at}uci.edu

Babak Kasravi, MD

Department of Medicine, Division of Cardiology, University of California, Irvine Medical Center, Orange, California

Charles S. Bryan, MD

Department of Medicine, University of South Carolina School of Medicine, Columbia, South Carolina

The recent appearance of Staphylococcus aureus and Staphylococcus epidermidis strains that have reduced susceptibility to vancomycin, and the spread of vancomycin-resistant enterococci, raise the specter of endovascular infections that will be difficult or impossible to cure with available drugs. We review issues concerning the prophylactic use of vancomycin in adult cardiology and cardiac surgery with special attention to dosing and indications. There is no indication for the routine use of prophylactic vancomycin in pacemaker implantations, cardiac catheterization, and transesophageal echocardiography. In institutions with a high incidence of methicillin-resistant S. aureus and S. epidermidis, vancomycin may be used for antibiotic prophylaxis in place of cephalosporins for pacemaker or defibrillator implantation. The strongest evidence in support of the prophylactic use of vancomycin is during cardiac surgeries, particularly valvular surgeries in institutions with a high prevalence of methicillin-resistant S. aureus and S. epidermidis. When vancomycin is used prior to open heart surgery, the dose should be 15 mg/kg rather than the standard 1 g dose that is often recommended in the literature and used by 85% of institutional pharmacists who responded to our survey. Cardiologists and cardiac surgeons should assume leadership roles in promoting its responsible use.

Key Words: vancomycin • endocarditis • prophylaxis • cardiology • cardiac surgery

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 9, No. 1, 13-20 (2004)
DOI: 10.1177/107424840400900i103


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. H. S. Kwakman, A. A. te Velde, C. M. J. E. Vandenbroucke-Grauls, S. J. H. van Deventer, and S. A. J. Zaat Treatment and Prevention of Staphylococcus epidermidis Experimental Biomaterial-Associated Infection by Bactericidal Peptide 2 Antimicrob. Agents Chemother., December 1, 2006; 50(12): 3977 - 3983. [Abstract] [Full Text] [PDF]

				K. W. Garey, T. Dao, H. Chen, P. Amrutkar, N. Kumar, M. Reiter, and L. O. Gentry Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections J. Antimicrob. Chemother., September 1, 2006; 58(3): 645 - 650. [Abstract] [Full Text] [PDF]